These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25818517)

  • 21. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients.
    Falck P; Asberg A; Byberg KT; Bremer S; Bergan S; Reubsaet JL; Midtvedt K
    Transplantation; 2008 Nov; 86(10):1379-83. PubMed ID: 19034006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.
    Zgheib NK; Alameddine R; Massoud R; Nasr R; Zahreddine A; El Cheikh J; Mahfouz R; Bazarbachi A
    Curr Res Transl Med; 2020 Apr; 68(2):51-58. PubMed ID: 32094096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
    Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
    Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.
    Lukas JC; Suárez AM; Valverde MP; Calvo MV; Lanao JM; Calvo R; Suarez E; Gil AD
    J Clin Pharm Ther; 2005 Dec; 30(6):549-57. PubMed ID: 16336287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
    Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
    Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: a retrospective study.
    Feng H; Wang X; Zheng W; Liu S; Jiang H; Lin Y; Qiu H; Chan TF; Huang M; Li Y; Mo X; Li J
    BMJ Paediatr Open; 2023 Aug; 7(1):. PubMed ID: 37643815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
    Fanta S; Niemi M; Jönsson S; Karlsson MO; Holmberg C; Neuvonen PJ; Hoppu K; Backman JT
    Pharmacogenet Genomics; 2008 Feb; 18(2):77-90. PubMed ID: 18192894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.
    Kuzuya T; Kobayashi T; Moriyama N; Nagasaka T; Yokoyama I; Uchida K; Nakao A; Nabeshima T
    Transplantation; 2003 Sep; 76(5):865-8. PubMed ID: 14501869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of polymorphism of
    Wang L; Zeng G; Li J; Luo J; Li H; Zhang Z
    Xenobiotica; 2021 Jul; 51(7):852-858. PubMed ID: 33974505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients.
    Elnaggar M; Hafez H; Abdallah A; Hamza M; Khalaf MM; El-Haddad A
    J Oncol Pharm Pract; 2024 Sep; 30(6):983-991. PubMed ID: 37528663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis.
    Moiseev IS; Burmina EA; Muslimov AR; Pirogova OV; Bondarenko SN; Darskaya EI; Tarakanova YA; Senina NG; Afanasyev BV
    Ann Hematol; 2017 Jun; 96(6):935-942. PubMed ID: 28343273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
    Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
    Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients.
    Rosenbaum SE; Baheti G; Trull AK; Akhlaghi F
    Ther Drug Monit; 2005 Apr; 27(2):116-22. PubMed ID: 15795639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.
    Mao JJ; Jiao Z; Yun HY; Zhao CY; Chen HC; Qiu XY; Zhong MK
    Br J Clin Pharmacol; 2018 Jan; 84(1):153-171. PubMed ID: 28891596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant.
    Waterhouse T; Baron K; Eure W; Chen C; Dirks NL; Jansson J; Akbari M; Mehrotra S
    Pharmacol Res Perspect; 2024 Oct; 12(5):e1257. PubMed ID: 39233318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.
    Onizuka M; Kunii N; Toyosaki M; Machida S; Ohgiya D; Ogawa Y; Kawada H; Inoko H; Ando K
    Bone Marrow Transplant; 2011 Aug; 46(8):1113-7. PubMed ID: 21102498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.
    Atiq F; Broers AE; Andrews LM; Doorduijn JK; Koch BC; Van Gelder T; Versmissen J
    Eur J Clin Pharmacol; 2016 Jun; 72(6):719-23. PubMed ID: 26965514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.